

November 8, 2017



Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

GERMANTOWN, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, MD, FACR, FACP, as Chief Medical Officer.

“Given his extensive experience in the biopharma industry, Dr. Recker brings to Neuralstem an expertise that will be critical to the development of our clinical and preclinical pipeline, especially as we continue to plan our path forward,” said Rich Daly, Chairman and CEO, Neuralstem. “Dr. Recker has managed execution of all elements of clinical strategy, including trial development, data interpretation and product registration. These qualifications among myriad others make him an excellent addition to our organization.”

Dr. David Recker is the founding manager of JJK Consulting, a group that advises on pharmaceutical development, with an emphasis on global implementation of small molecule clinical trial design as well as a therapeutic focus on cell therapy. Dr. Recker serves as the Chief Medical Officer of Vericel Corporation, where he has been responsible for clinical development, regulatory affairs, medical and scientific affairs, pharmacovigilance, statistics and data management. Previously, Dr. Recker was Senior Vice President, Clinical Sciences with Takeda’s Global Research and Development division, where he implemented global clinical development strategies for several pharmacologic agents in multiple therapeutic areas. Dr. Recker completed his M.D. with distinction at the University of Michigan Medical School.

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward-looking statements” made pursuant to the “safe

harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three months ended March 31, 2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:

Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com

Source: Neuralstem, Inc.